These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38798554)

  • 1. Immunotherapy-related cognitive impairment after CAR T cell therapy in mice.
    Geraghty AC; Acosta-Alvarez L; Rotiroti M; Dutton S; O'Dea MR; Woo PJ; Xu H; Shamardani K; Mancusi R; Ni L; Mulinyawe SB; Kim WJ; Liddelow SA; Majzner RG; Monje M
    bioRxiv; 2024 May; ():. PubMed ID: 38798554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain.
    Fernández-Castañeda A; Lu P; Geraghty AC; Song E; Lee MH; Wood J; Yalçın B; Taylor KR; Dutton S; Acosta-Alvarez L; Ni L; Contreras-Esquivel D; Gehlhausen JR; Klein J; Lucas C; Mao T; Silva J; Peña-Hernández MA; Tabachnikova A; Takahashi T; Tabacof L; Tosto-Mancuso J; Breyman E; Kontorovich A; McCarthy D; Quezado M; Hefti M; Perl D; Folkerth R; Putrino D; Nath A; Iwasaki A; Monje M
    bioRxiv; 2022 Jan; ():. PubMed ID: 35043113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation.
    Fernández-Castañeda A; Lu P; Geraghty AC; Song E; Lee MH; Wood J; O'Dea MR; Dutton S; Shamardani K; Nwangwu K; Mancusi R; Yalçın B; Taylor KR; Acosta-Alvarez L; Malacon K; Keough MB; Ni L; Woo PJ; Contreras-Esquivel D; Toland AMS; Gehlhausen JR; Klein J; Takahashi T; Silva J; Israelow B; Lucas C; Mao T; Peña-Hernández MA; Tabachnikova A; Homer RJ; Tabacof L; Tosto-Mancuso J; Breyman E; Kontorovich A; McCarthy D; Quezado M; Vogel H; Hefti MM; Perl DP; Liddelow S; Folkerth R; Putrino D; Nath A; Iwasaki A; Monje M
    Cell; 2022 Jul; 185(14):2452-2468.e16. PubMed ID: 35768006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment.
    Gibson EM; Monje M
    Curr Opin Oncol; 2019 Nov; 31(6):531-539. PubMed ID: 31449084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment.
    Gibson EM; Nagaraja S; Ocampo A; Tam LT; Wood LS; Pallegar PN; Greene JJ; Geraghty AC; Goldstein AK; Ni L; Woo PJ; Barres BA; Liddelow S; Vogel H; Monje M
    Cell; 2019 Jan; 176(1-2):43-55.e13. PubMed ID: 30528430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice.
    Sanchez-Ramos J; Song S; Sava V; Catlow B; Lin X; Mori T; Cao C; Arendash GW
    Neuroscience; 2009 Sep; 163(1):55-72. PubMed ID: 19500657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglia in Cancer Therapy-Related Cognitive Impairment.
    Gibson EM; Monje M
    Trends Neurosci; 2021 Jun; 44(6):441-451. PubMed ID: 33674135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.
    Fischbach F; Richter J; Pfeffer LK; Fehse B; Berger SC; Reinhardt S; Kuhle J; Badbaran A; Rathje K; Gagelmann N; Borie D; Seibel J; Ayuk F; Friese MA; Heesen C; Kröger N
    Med; 2024 Jun; 5(6):550-558.e2. PubMed ID: 38554710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.
    Huang J; Li YB; Charlebois C; Nguyen T; Liu Z; Bloemberg D; Zafer A; Baumann E; Sodja C; Leclerc S; Fewell G; Liu Q; Prabhakarpandian B; McComb S; Stanimirovic DB; Jezierski A
    Fluids Barriers CNS; 2022 Jun; 19(1):38. PubMed ID: 35650594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy.
    Song KW; Scott BJ; Lee EQ
    Curr Neurol Neurosci Rep; 2023 Dec; 23(12):827-839. PubMed ID: 37938472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurologic Toxicities of Cancer Immunotherapies: a Review.
    Harrison RA; Tummala S; de Groot J
    Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review.
    Liu Y; Li Y; Yu Z; Wang R; Jing Y
    Front Oncol; 2024; 14():1341682. PubMed ID: 38322417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
    Kline K; Luetkens T; Koka R; Kallen ME; Chen W; Ahmad H; Omili D; Iraguha T; Gebru E; Fan X; Miller A; Dishanthan N; Baker JM; Dietze KA; Hankey KG; Yared JA; Hardy NM; Rapoport AP; Dahiya S; Atanackovic D
    Cancer Immunol Immunother; 2024 Feb; 73(3):45. PubMed ID: 38349430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
    Adachi K; Tamada K
    Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
    Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
    Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
    Das S; Valton J; Duchateau P; Poirot L
    Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.
    Pellizzari G; Martinez O; Crescioli S; Page R; Di Meo A; Mele S; Chiaruttini G; Hoinka J; Batruch I; Prassas I; Grandits M; López-Abente J; Bugallo-Blanco E; Ward M; Bax HJ; French E; Cheung A; Lombardi S; Figini M; Lacy KE; Diamandis EP; Josephs DH; Spicer J; Papa S; Karagiannis SN
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34112739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.